Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zoltan Grosz is active.

Publication


Featured researches published by Zoltan Grosz.


Neuromuscular Disorders | 2016

Three novel mutations and genetic epidemiology analysis of the Gap Junction Beta 1 (GJB1) gene among Hungarian Charcot-Marie-Tooth disease patients.

György Máté Milley; Edina Timea Varga; Zoltan Grosz; Benjamin Bereznai; Zsuzsanna Arányi; Judit Boczán; P. Diószeghy; Bernadette Kalman; Anikó Gál; Mária Judit Molnár

Pathogenic variants of the gap junction beta 1 (GJB1) gene are responsible for the Charcot-Marie-Tooth neuropathy X type 1 (CMTX1). In this study, we report the mutation frequency of GJB1 in 210 Hungarian CMT patients and the phenotype comparison between male and female CMTX1 patients. Altogether, 13 missense substitutions were found in the GJB1 gene. Among them, 10 have been previously described as pathogenic variants (p.Arg15Trp, p.Val63Ile, p.Leu89Val, p.Ala96Gly, p.Arg107Trp, p.Arg142Gln, p.Arg164Trp, p.Arg164Gln, p.Pro172Ala and p.Asn205Ser), while 3 were novel, likely pathogenic alterations (p.Val13Glu, p.Glu186Gly, p.Met194Ile). These variants were not present in controls and were predicted as disease causing by in silico analysis. The frequency of the variants was 6.7% in our cohort which refers to a common cause of hereditary neuropathy among Hungarian patients. In addition to the classical phenotype, CNS involvement was proved in 26.1% of the CMTX1 patients. GJB1 pathogenic alterations were found mainly in males but we also detected them in female probands. The statistical analysis of CMTX1 patients revealed a significant difference between the two genders regarding the age of onset, Charcot-Marie-Tooth neuropathy and examination scores.


Journal of the Neurological Sciences | 2016

Genetic background of the hereditary spastic paraplegia phenotypes in Hungary - An analysis of 58 probands

Peter Balicza; Zoltan Grosz; Michael Gonzalez; Renáta Bencsik; Klara Pentelenyi; Anikó Gál; Edina Varga; Péter Klivényi; Júlia Koller; Stephan Züchner; Mária Judit Molnár

BACKGROUND Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative diseases with progressive lower limb spasticity and weakness. The aim of this study is to determine the frequency of different SPG mutations in Hungarian patients, and to provide further genotype-phenotype correlations for the known HSP causing genes. METHODS We carried out genetic testing for 58 probands with clinical characteristics of HSP. For historical reasons, three different approaches were followed in different patients: 1) Sanger sequencing of ATL1 and SPAST genes, 2) whole exome, and 3) targeted panel sequencing by next generation sequencing. RESULTS Genetic diagnosis was established for 20 probands (34.5%). We detected nine previously unreported mutations with high confidence for pathogenicity. The most frequently affected gene was SPAST with pathogenic or likely pathogenic mutations in 10 probands. The most frequently detected variant in our cohort was the SPG7 p.Leu78*, observed in four probands. Altogether five probands were diagnosed with SPG7. Additional mutations were detected in SPG11, ATL1, NIPA1, and ABCD1. CONCLUSION This is the first comprehensive genetic epidemiological study of patients with HSP in Hungary. Next generation sequencing improved the yield of genetic diagnostics in this disease group even when the phenotype was atypical. However, considering the frequency of the HSP-causing gene defects, SPG4, the most common form of the disease, should be tested first to be cost effective in this economic region.


The Epma Journal | 2018

Implementation of personalized medicine in Central-Eastern Europe: pitfalls and potentials based on citizen’s attitude

Peter Balicza; András Terebessy; Zoltan Grosz; Noémi Ágnes Varga; Anikó Gál; Bálint Fekete; Mária Judit Molnár

ObjectiveNext-generation sequencing is increasingly utilized worldwide as a research and diagnostic tool and is anticipated to be implemented into everyday clinical practice. Since Central-Eastern European attitude toward genetic testing, especially broad genetic testing, is not well known, we performed a survey on this issue among Hungarian participants.MethodsA self-administered questionnaire was distributed among patients and patient relatives at our neurogenetic outpatient clinic. Members of the general population were also recruited via public media. We used chi-square testing and binary logistic regression to examine factors influencing attitude.ResultsWe identified a mixed attitude toward genetic testing. Access to physician consultation positively influenced attitude. A higher self-determined genetic familiarity score associated with higher perceived genetic influence score, which in turn associated with greater willingness to participate in genetic testing. Medical professionals constituted a skeptical group.ConclusionsWe think that given the controversies and complexities of the next-generation sequencing field, the optimal clinical translation of NGS data should be performed in institutions which have the unique capability to provide interprofessional health education, transformative biomedical research, and crucial patient care. With optimization of the clinical translational process, improvement of genetic literacy may increase patient engagement and empowerment.Relevance of the article for predictive, preventive, and personalized medicineThe paper highlights that in countries with relatively low-genetic literacy, a special strategy is needed to enhance the implementation of personalized medicine.


Orvosi Hetilap | 2018

A teljesexom-szekvenálás jelentősége a ritka neurológiai betegségek diagnosztikájában – saját tapasztalatok egy ataxiás eset kapcsán

Peter Balicza; Zoltan Grosz; Renáta Bencsik; Anett Illés; Anikó Gál; András Gézsi; Mária Judit Molnár

Next generation sequencing (NGS) technologies reshape the diagnostics of rare neurological diseases. In the background of certain neurological symptoms, such as ataxia, many acquired and genetic causes may be present. Variations in a given gene can present with variable phenotypes, too. Because of this phenomenon, the conventional one gene sequencing approach often fails to identify the genetic background of a disease. Next generation sequencing panels allow to sequence 50-100 genes simultaneously, and if the disease stratification is not possible based on the clinical symptoms, whole exome sequencing can help in the diagnostic of genetic disorders with atypical presentation. This case study is about the exome sequencing of a patient with cerebellar ataxia. Genetic investigations identified rare variants in the SPG11 gene in association with the clinical phenotype, which gene was originally described in the background of hereditary spastic paraparesis. Our article highlights that in certain cases the variability of the leading presenting symptom makes it hard to select the correct gene panel. In our case the variants in the gene, formerly associated to hereditary spastic paraparesis, resulted in cerebellar ataxia initially, so even an ataxia NGS gene panel would not detect those. Orv Hetil. 2018; 159(28): 1163-1169.Next generation sequencing (NGS) technologies reshape the diagnostics of rare neurological diseases. In the background of certain neurological symptoms, such as ataxia, many acquired and genetic causes may be present. Variations in a given gene can present with variable phenotypes, too. Because of this phenomenon, the conventional one gene sequencing approach often fails to identify the genetic background of a disease. Next generation sequencing panels allow to sequence 50-100 genes simultaneously, and if the disease stratification is not possible based on the clinical symptoms, whole exome sequencing can help in the diagnostic of genetic disorders with atypical presentation. This case study is about the exome sequencing of a patient with cerebellar ataxia. Genetic investigations identified rare variants in the SPG11 gene in association with the clinical phenotype, which gene was originally described in the background of hereditary spastic paraparesis. Our article highlights that in certain cases the variability of the leading presenting symptom makes it hard to select the correct gene panel. In our case the variants in the gene, formerly associated to hereditary spastic paraparesis, resulted in cerebellar ataxia initially, so even an ataxia NGS gene panel would not detect those. Orv Hetil. 2018; 159(28): 1163-1169.


Neuromuscular Disorders | 2018

Genotypic and phenotypic spectrum of the most common causative genes of Charcot-Marie-Tooth disease in Hungarian patients

György Máté Milley; Edina Timea Varga; Zoltan Grosz; Csilla Nemes; Zsuzsanna Arányi; Judit Boczán; P. Diószeghy; Mária Judit Molnár; Anikó Gál

Charcot-Marie-Tooth neuropathy (CMT) is a genetically and clinically heterogeneous group of neuromuscular disorders with an overall prevalence of 1 per 2500. Here we report the first comprehensive genetic epidemiology study of Hungarian CMT patients. 409 CMT1 and 122 CMT2 patients were enrolled and genetic testing of PMP22, GJB1, MPZ, EGR2 and MFN2 genes were performed routinely. NDRG1 and CTDP1 genes were screened only for founder mutations in Roma patients. Causative genetic mutations were identified in 67.2% of the CMT1 and in 33.6% of the CMT2 cases, which indicates an overall success rate of 59.9% in the study population. Considering all affected individuals, alterations were most frequently found in PMP22 (40.5%), followed by GJB1 (9.2%), MPZ (4.5%), MFN2 (2.5%), NDRG1 (1.5%), EGR2 (0.8%) and CTDP1 (0.8%). The phenotypic spectrum and the disease severity of the studied patients also varied broadly. Deafness and autoimmune disorders were more often associated with PMP22 duplication, while MFN2 and GJB1 mutations were frequently present with central nervous system abnormalities. Our study may be helpful in determining the strategy of genetic diagnostics in Hungarian CMT patients.


Frontiers in Genetics | 2018

NKX2-1 New Mutation Associated With Myoclonus, Dystonia, and Pituitary Involvement

Peter Balicza; Zoltan Grosz; Viktor Molnár; Anett Illés; Dora Csabán; András Gézsi; Livia Dézsi; Dénes Zádori; László Vécsei; Mária Judit Molnár

Background: NKX2-1 related disorders (also known as brain-lung-thyroid syndrome or benign hereditary chorea 1) are associated with a wide spectrum of symptoms. The core features are various movement disorders, characteristically chorea, less frequently myoclonus, dystonia, ataxia; thyroid disease; and lung involvement. The full triad is present in 50% of affected individuals. Numerous additional symptoms may be associated, although many of these were reported only in single cases. Pituitary dysfunction was ambiguously linked to NKX2-1 haploinsufficiency previously. Case Presentation: We examined two members of a family with motor developmental delay, mixed movement disorder (myoclonus, dystonia and chorea) and endocrinological abnormalities (peripheric thyroid disease, and pituitary hormone deficiencies). Dystonia predominated at the father, and myoclonus at the daughter. The father had hypogonadotropic hypogonadism, while the daughter was treated with growth hormone deficiency. Both patients had empty sella on MRI. Candidate gene analyses were negative. Exome sequencing detected a pathogenic stop variation (NM_003317:c.338G>A, p.Trp113*) in the NKX2-1 gene. Conclusions: This case study has two highlights. (1) It draws attention to possible pituitary dysfunction in brain-lung-thyroid syndrome, and provide further evidences that this might be linked to loss of function of the NKX2-1 gene. (2) It underscores the importance of considering NKX2-1 related disorders in the differential diagnosis of myoclonus dystonia.


Journal of Neurology, Neurosurgery, and Psychiatry | 2016

B28 Combined replication malfunctions in huntington’s disease

Zoltan Grosz; Danuta Szirmai; Viktoria Remenyi; Renáta Bencsik; Judit Molnár

Background Huntington’s disease (HD) is a monogenic disease caused by the CAG repeat expansion of the IT15 gene. The underlying molecular mechanism of the disease is related to the toxic huntingtin protein aggregates. Mitochondrial dysfunction was observed, as well. The involvement and role of mitochondrial repair mechanism in the disease pathogenesis is not widely studied. RAD51 is one of the genes playing a role in the mitochondrial DNA repair mechanism of cells. Aims To use a genomic approach to better understand the mitochondrial dysfunction observed in HD. We examined the presence of mt DNA deletion and in positive cases RAD51 gene in genetically confirmed Huntington’s patients assuming that besides IT15 mutation other genetic factors might be responsible for disease manifestation. Methods One hundred genetically confirmed HD patients were compared to two control groups that included 100 subjects each. One of the contol groups was patients included PMP22 deletion/duplication, while the other was made up from healty subjects. Mt DNA deletion was diagnosed with long PCR technic. RAD51 gene were analysed by direct Sanger sequencing. Results Mt DNA deletion was found in 25 cases regarding Huntington’s disease patients and 12 cases in PMP22 copy number variants group, while among healthy controls there were only 6 cases. The mt DNA deletion was not correlated with age in any of the cohorts. No mutation in RAD51gene was detected. Conclusion Mutation of mt DNA is significantly higher in the HD group, but mutations in gene RAD51 responsible for mitochondrial repair were not detected. It would be worth to consider analysing other genes playing a role in the mitochondrial repair mechanism.


Journal of Neurology, Neurosurgery, and Psychiatry | 2018

H20 Initiating and setting up a patient advocacy group for huntington’s disease in hungary

Zoltan Grosz; Győző Pék; Györgyi Báthori; Judit Molnár


Cardiologia Hungarica | 2017

Mitokondriális génmutáció igazolása dominálóan hipertrófiás cardiomyopathia képében megjelenő szisztémás kórképben

Annamária Tringer; Zoltan Grosz; Viktória Nagy; Anikó Gál; Beáta Csányi; Lidia Hategan; János Borbás; Henriette Gavallér; Eszter Pálinkás; Tamás Forster; Mária Judit Molnár; Róbert Sepp


Neurology | 2016

Genetic Background of the Hereditary Spastic Paraplegia Phenotypes in Hungary (P5.049)

Mária Judit Molnár; Peter Balicza; Zoltan Grosz; Michael Gonzalez; Renáta Bencsik; Klara Pentelenyi; Anikó Gál; Edina Varga; Péter Klivényi; Stephan Züchner

Collaboration


Dive into the Zoltan Grosz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge